Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Shweta R. Urva"'
Autor:
Michael Frost, Shweta R. Urva, David Chen, John J. Bissler, Klemens Budde, Bernard A. Zonnenberg, Karen Stein, Wing Cheung, Thomas Brechenmacher, J. C. Kingswood
Publikováno v:
British Journal of Clinical Pharmacology. 81:958-970
Aims The purpose was to determine the exposure-response relationship of everolimus in patients with angiomyolipoma from the EXIST-2 trial and to analyze the correlation between exposure and plasma concentrations of angiogenic biomarkers in these pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::680292dae007703ac29ba44aa778ebf7
https://doi.org/10.1111/bcp.12834
https://doi.org/10.1111/bcp.12834
Autor:
Peter E. Schwartz, Thomas J. Rutherford, Susan A. Higgins, Maysa M. Abu-Khalaf, Masoud Azodi, Dan-Arin Silasi, Elena Ratner, Carlos Rodrigo Acevedo-Gadea, Shweta R. Urva, Alessandro D. Santin
Publikováno v:
International Journal of Gynecologic Cancer. 24:528-533
ObjectivesPreclinical data suggest that mammalian target of rapamycin inhibitors may potentiate the efficacy of topotecan. We evaluated the optimal schedule of oral topotecan in combination with everolimus in patients with endometrial cancer.MethodsW
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::246c6b683101bc1f72bff02bec76d10e
https://doi.org/10.1097/igc.0000000000000085
https://doi.org/10.1097/igc.0000000000000085
Publikováno v:
European Journal of Cancer. 50:486-495
Background In patients with solid tumours, daily everolimus dosing demonstrated dose proportionality and linear pharmacokinetics. A meta-analysis was conducted to characterise the relationship between everolimus C min and efficacy and safety and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7677debe4490a28556e43fae647632
https://doi.org/10.1016/j.ejca.2013.11.022
https://doi.org/10.1016/j.ejca.2013.11.022
Autor:
Paul Mitchell, Jeffrey J. De Leo, Joan H. Schiller, Sven Gogov, Valentine Jehl, Glenn Mills, Vassiliki A. Papadimitrakopoulou, Wilfried Eberhardt, Shweta R. Urva, Michael P. Brown, Michael Thomas
Publikováno v:
Investigational New Drugs. 32:123-134
Introduction One standard of care for advanced non–small cell lung cancer (NSCLC) is paclitaxel plus carboplatin ± bevacizumab. This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin ± bevacizuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d55cca4c0d7e4bc4d456363e38688c36
https://doi.org/10.1007/s10637-013-9958-3
https://doi.org/10.1007/s10637-013-9958-3
Publikováno v:
The Journal of Clinical Pharmacology. 53:444-450
The selective mammalian target of rapamycin (mTOR) inhibitor everolimus has demonstrated competitive inhibition of cytochrome P450 enzyme (CYP) 3A4 in vitro; however, its influence on CYP3A4 activity in humans is unknown. This study examined the infl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a738917bda822d5cff3df20d81d6bb7
https://doi.org/10.1002/jcph.7
https://doi.org/10.1002/jcph.7
Autor:
Mary MacNeil, L. McIntosh, Elizabeth Eisenhauer, Warren P. Mason, David R. Macdonald, Brian Thiessen, Zarnie Lwin, Petr Kavan, Jacob C. Easaw, Shweta R. Urva
Publikováno v:
Investigational New Drugs. 30:2344-2351
Purpose This phase I trial was designed to determine the recommended phase II dose(s) of everolimus (RAD001) with temozolomide (TMZ) in patients with glioblastoma (GBM). Patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) and those not re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e30c2146acb508994aa9e37acc5a0e76
https://doi.org/10.1007/s10637-011-9775-5
https://doi.org/10.1007/s10637-011-9775-5
Publikováno v:
Journal of Immunoassay and Immunochemistry. 31:1-9
T84.66 is a monoclonal antibody with high affinity and specificity for tumor-associated carcinoembryonic antigen (CEA). In this work, we have developed an enzyme linked immunosorbent assay to determine T84.66 concentrations in mouse plasma. The assay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2608cd5e4c6b6486ea84d8b9eadf5cd8
https://doi.org/10.1080/15321810903404772
https://doi.org/10.1080/15321810903404772
Publikováno v:
Journal of Immunoassay and Immunochemistry. 30:418-427
Carcinoembryonic antigen (CEA) is a tumor associated antigen that is over-expressed in colorectal cancer and several other cancers of the gastrointestinal system. An enzyme linked immunosorbent assay was developed to determine CEA concentrations in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4596234e1247286e1dabe0af362c0307
https://doi.org/10.1080/15321810903188227
https://doi.org/10.1080/15321810903188227
Autor:
Tiffany Kunz, Jan Peveling-Oberhag, Zhanna Kobalava, Oezlem Anak, Dalila Sellami, Thierry Paquet, Wei Peng Yong, Emmanuel Bouillaud, Shweta R. Urva, Stefan Zeuzem
Publikováno v:
Clinical therapeutics. 35(3)
Background Although the pharmacokinetics of everolimus, an oral mammalian target of rapamycin inhibitor, have been characterized in patients with moderate hepatic impairment, they have not been assessed in those with mild or severe hepatic impairment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aac98965356aca32abd067ef41cad40
https://pubmed.ncbi.nlm.nih.gov/23453404
https://pubmed.ncbi.nlm.nih.gov/23453404
Autor:
Joseph P. Balthasar, Shweta R. Urva
Publikováno v:
mAbs. 2(1)
Carcinoembryonic antigen (CEA) is a glycosylated cell surface antigen known to be highly overexpressed in several adenocarcinomas, including colorectal cancer, while demonstrating limited expression in normal tissues. Prior work has shown that the pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17eba3d7cf49e30cb03eee28c3b462ea
https://pubmed.ncbi.nlm.nih.gov/20081377
https://pubmed.ncbi.nlm.nih.gov/20081377